Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare immune disorder: ruxolitinib trial targets castleman disease

NCT ID NCT07085039

Recruiting now Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug ruxolitinib in 14 adults with idiopathic multicentric Castleman disease (iMCD) whose condition did not improve with standard therapies like siltuximab or tocilizumab. The goal is to see if ruxolitinib can improve symptoms such as fatigue, fever, and night sweats, as well as lab markers and lymph node size. Participants will take the drug and be monitored for up to 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTLEMAN'S DISEASE (CD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Castleman disease idiopathic multicentric Castleman disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTLEMAN'S DISEASE (CD) IDIOPATHIC MULTICENTRIC CASTLEMAN'S DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact